COMMUNIQUÉS West-GlobeNewswire

RavenQuest Lists Warrants
29/06/2018
VANCOUVER, British Columbia, June 29, 2018 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE:RQB) (OTCQB:RVVQF) (Frankfurt:1IT) ( “ RavenQuest ”) is pleased to announce that warrants issued pursuant to its February 28, [...]
Leading International CBD Brand Gears Up to Go Public -- CFN Media
29/06/2018
Seattle, WA , June 29, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article [...]
New Alliance Seeks to Promote Health and Prevent Illness by Addressing Social Determinants of Health in Ogden, St. George
29/06/2018
Intermountain Healthcare involves city, county, and state government agencies and other community based organizations to come together to promote health, improve health care access, and decrease health care costs. Salt [...]
News Release: Essilor and Delfin extend the deadline of the Combination Agreement - EssilorLuxottica General Meeting to be reconvened
29/06/2018
Essilor and Delfin extend the deadline of the Combination Agreement EssilorLuxottica General Meeting to be reconvened PDF version of the news release Charenton-le-Pont, France, and Milan, Italy, ( June 29, 2018 ) - [...]
Communiqué: Essilor et Delfin prolongent le terme de l'accord de rapprochement - Report de l'Assemblée Générale d'EssilorLuxottica
29/06/2018
Essilor et Delfin prolongent le terme de l'accord de rapprochement Report de l'Assemblée Générale d'EssilorLuxottica Version PDF du communiqué Charenton-le-Pont, France et Milan, Italie (le 29 juin 2018) - Essilor et [...]
Kalytera Announces Appointment of Victoria Rudman as Interim Chief Financial Officer and Additional Payments in Shares under Payments Agreements with Salzman Group
29/06/2018
SAN FRANCISCO and TEL AVIV, Israel, June 29, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF) (the " Company " or " Kalytera ") today announced the appointment of Victoria Rudman as [...]
BLVD Centers Posts Audited Financial Statements for Period Ending February 28, 2018
29/06/2018
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES LOS ANGELES, June 29, 2018 (GLOBE NEWSWIRE) -- BLVD Centers Corporation (“ BLVD ” or the “ Company ”) (CSE:BLVD), today [...]
HuMax®-AXL-ADC Progress Triggers Milestone Payment to Seattle Genetics
29/06/2018
Company Announcement Genmab to pay Seattle Genetics, Inc. a milestone payment of USD 7 million under the Antibody-Drug Conjugate (ADC) program targeting AXL Milestone triggered by clinical progress in the Phase I/II [...]
Alzheimer’s Foundation of America’s Statement on Senate Appropriations Committee Approval of FY 2019 Funding Increase for Alzheimer’s Disease Research
29/06/2018
NEW YORK, June 29, 2018 (GLOBE NEWSWIRE) -- The Senate Appropriations Committee approved a package that includes a $425 million increase in funding for Alzheimer’s disease research at the National Institutes of Health ( [...]
Innovation Pharmaceuticals Announces Database Lock for Phase 2b Trial of Oral Prurisol for Psoriasis
29/06/2018
BEVERLY, Mass., June 29, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces database lock for its Phase 2b clinical trial of [...]
RavenQuest Eyes Massive Micro Cultivation Market -- CFN Media
29/06/2018
SEATTLE, June 29, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article [...]
Newly Public, James E. Wagner Cultivation Moves Toward Cannabis Oils -- CFN Media
29/06/2018
SEATTLE, June 29, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing [...]
Ultragenyx Announces Positive CHMP Opinion for Mepsevii™ (vestronidase alfa) For the Treatment of Mucopolysaccharidosis VII
29/06/2018
NOVATO, Calif., June 29, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European [...]
Devonian Announces Grant of Options
29/06/2018
QUEBEC CITY, June 29, 2018 (GLOBE NEWSWIRE) -- Devonian Health Group Inc. (" Devonian " or the " Corporation ") (TSX VENTURE:GSD) announces that the Board of Directors has approved the grant of options (the ‘‘Options [...]
Devonian annonce l’octroi d’options
29/06/2018
QUÉBEC, 29 juin 2018 (GLOBE NEWSWIRE) -- Groupe Santé Devonian Inc. (« Devonian » ou la « Société ») (TSX CROISSANCE:GSD) annonce que le conseil d'administration a approuvé l'octroi d'options (les «options») pour [...]
Emisphere Development Update
29/06/2018
ROSELAND, N.J., June 29, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk announced yesterday the completion and results of the phase 3a trial, PIONEER 3, with oral semaglutide, a once-daily oral formulation of the long-acting GLP [...]
Alder BioPharmaceuticals® Presents New Six-Month Data for Eptinezumab Demonstrating Improvement in Efficacy in PROMISE 2 Phase 3 Trial for Chronic Migraine
29/06/2018
- Data presented today at the American Headache Society (AHS) Annual Scientific Meeting demonstrate 43% of patients receiving 300 mg of eptinezumab achieved a 75% or greater reduction of monthly migraine days - 1 in 5 [...]
Alder BioPharmaceuticals® Presents New One-Year Data for Eptinezumab from PROMISE 1 Phase 3 Trial Demonstrating Long-Term Efficacy in Episodic Migraine
29/06/2018
- Data presented today at the American Headache Society (AHS) Annual Scientific Meeting demonstrate eptinezumab’s robust efficacy is further improved at one year following third and fourth quarterly infusions - [...]
AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency
29/06/2018
NEW YORK, June 29, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal [...]

Pages